ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market
Holding AVBP?
Track your performance easily

ArriVent BioPharma, Inc. (AVBP) Ownership - Who Owns ArriVent BioPharma, Inc.?

22 Followers

ArriVent BioPharma, Inc. (AVBP) Ownership Overview

28.96%8.83%8.98%8.19%45.05%
28.96% Insiders
8.98% Other Institutional Investors
8.19% ETFs
45.05% Public Companies and
Individual Investors
The ownership structure of ArriVent BioPharma, Inc. (AVBP) stock is a mix of institutional, retail, and individual investors. Approximately 25.99% of the company’s stock is owned by Institutional Investors, 28.96% is owned by Insiders, and 45.05% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Feb 01, 2024
xxxxxxxxxxxxx
$9999990
Jan 31, 2024
Orbimed Advisors Llc
Director, >10% Owner
xxxxxxxxxxxxx
$7999992
Jan 31, 2024
Carl Gordon
Director, >10% Owner
xxxxxxxxxxxxx
$7999992
Jan 31, 2024
James Healy
Director
xxxxxxxxxxxxx
$7999992

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
4,484,672Insider13.35%153,330,936
1,950,000Institution5.81%66,670,500
1,696,752Insider5.05%58,011,951
1,513,664Insider4.51%51,752,172
1,513,664Insider4.51%51,752,172
1,272,025Institution3.79%43,490,535
1,115,736Institution3.32%38,147,014
573,842Institution1.71%19,619,658
519,060Insider1.55%17,746,661
415,000Institution1.24%14,188,850

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,950,000Institution5.81%66,670,500
573,842Institution1.71%19,619,658
112,544Institution0.34%3,847,879
111,782Institution0.33%3,821,827
86,000Institution0.26%2,940,340
48,432Institution0.14%1,655,890
28,447Institution0.08%972,603
12,932Institution0.04%442,145
8,443Institution0.03%288,666
7,689Institution0.02%262,887

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
766,839Institution2.28%26,218,225
784,202Institution2.33%18,428,747
335,208Institution1.00%7,877,388
152,155Institution0.45%5,202,179
107,469Institution0.32%3,829,120
107,255Institution0.32%3,821,496
105,789Institution0.31%3,616,926
126,599Institution0.38%2,975,077
63,886Institution0.19%2,184,262
28,534Institution0.08%975,577

FAQ

Who Owns ArriVent BioPharma, Inc. (AVBP)?
According to the latest TipRanks data, approximately 8.98% of the company's stock is held by institutional investors, 28.96% is held by insiders, and 45.05% is held by retail investors.
    What percentage of ArriVent BioPharma, Inc. (AVBP) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 8.98% of ArriVent BioPharma, Inc. (AVBP) stock is held by institutional investors.
      What percentage of ArriVent BioPharma, Inc. (AVBP) stock is held by retail investors?
      According to the latest TipRanks data, approximately 45.05% of ArriVent BioPharma, Inc. (AVBP) stock is held by retail investors.
        Who owns the most shares of ArriVent BioPharma, Inc. (AVBP)?
        Hillhouse Capital Management, Ltd. owns the most shares of ArriVent BioPharma, Inc. (AVBP).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis